Ankylosing Spondylitis Market Size Positioned for a Projected CAGR of 6.5% to Achieve a Valuation of USD 9.5 Billion by 2032

Acumen Research and Consulting recently published report titled “Ankylosing Spondylitis Market Forecast, 2023 – 2032”

LOS ANGELES, Sept. 13, 2023 (GLOBE NEWSWIRE) —  The Global Ankylosing Spondylitis Market Size accounted for USD 5.1 Billion in 2022 and is projected to achieve a market size of USD 9.5 Billion by 2032 growing at a CAGR of 6.5% from 2023 to 2032.

The Ankylosing Spondylitis Market is on track for continuous expansion globally, driven by the increasing prevalence of AS, advancements in treatment options, and a growing awareness of this chronic inflammatory disease. With the increasing prevalence of AS and ongoing research into the disease’s mechanisms, the market is poised for sustained growth, driven by advancements in treatment options and a holistic approach to managing this chronic inflammatory condition. Ankylosing spondylitis is a persistent inflammatory form of arthritis that predominantly impacts the spine and sacroiliac joints, resulting in discomfort, rigidity, and limited mobility. It can also affect other parts of the body, including the eyes and heart. This condition is characterized by inflammation and fusion of the vertebrae, leading to a rigid, hunched posture. Ankylosing spondylitis typically starts in early adulthood and is more common in men. While there is no cure, treatments like exercise, medications, and physical therapy can help manage symptoms and improve the quality of life for those with the condition.

Ankylosing Spondylitis Market Highlights and Key Stats:

  • The Global Ankylosing Spondylitis Market is projected to reach USD 9.5 billion by 2032, marking a substantial increase from its 2022 valuation of USD 5.1 billion, propelled by a steady CAGR of 6.5% from 2023 to 2032.
  • North America leads the market with the highest revenue share, surpassing 43.0% in 2022, due to a well-established healthcare infrastructure and a substantial AS patient population.
  • Medication dominates the treatment landscape, accounting for over 62.0% of the market share in 2022, offering targeted therapy for symptom relief and disease management.
  • The Ankylosing Spondylitis Market growth is further propelled by the increasing adoption of early diagnosis, effective treatment strategies, and patient support programs.

Request For Free Sample Report @

Ankylosing Spondylitis Market Report Coverage:

Market Ankylosing Spondylitis Market
Ankylosing Spondylitis Market Size 2022 USD 5.1 Billion
Ankylosing Spondylitis Market Forecast 2032 USD 9.5 Billion
Ankylosing Spondylitis Market CAGR During 2023 – 2032 6.5%  
Ankylosing Spondylitis Market Analysis Period 2020 – 2032
Ankylosing Spondylitis Market Base Year 2022  
Ankylosing Spondylitis Market Forecast Data 2023 – 2032
Segments Covered By Treatment Types, By End User, And By Geography
Ankylosing Spondylitis Market Regional Scope North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled AbbVie Inc., Amgen Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Merck & Co., Inc., and GlaxoSmithKline plc (GSK)
Report Coverage Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis

Ankylosing Spondylitis Market Analysis:

The Ankylosing Spondylitis (AS) Market encounters several significant challenges. One of the foremost issues is the complexity of diagnosing AS. Since its early symptoms, like back pain and stiffness, can be mistaken for other conditions, the accurate diagnosis often takes time and may lead to delayed treatment initiation.

Furthermore, AS exhibits variable disease progression, making it challenging to predict how the condition will evolve in each patient. This heterogeneity necessitates a personalized treatment approach, as what works for one individual may not be effective for another.

However, despite these challenges, the AS market is experiencing growth, largely attributed to advances in biologics. Biologic therapies, such as TNF-alpha inhibitors, have revolutionized AS treatment by targeting the inflammatory pathways underlying the disease. These medications have shown remarkable efficacy in alleviating symptoms and slowing disease progression, improving the quality of life for AS patients.

Additionally, ongoing research into the underlying mechanisms of AS is shedding light on potential new therapeutic targets. This has led to the development of novel treatment options, giving hope for more effective and tailored therapies in the future. Overall, while the AS market faces complexities, it is poised for continued growth and innovation in the field of rheumatology.

Latest Ankylosing Spondylitis Market Trends and Applications:

  • Targeted therapies that inhibit specific cytokines, such as tumor necrosis factor (TNF) and interleukin-17 (IL-17), are emerging as promising treatments for Ankylosing Spondylitis Market.
  • The integration of digital health solutions and telemedicine is improving patient monitoring, disease management, and access to specialized care.
  • Research into the genetics of Ankylosing Spondylitis Market is paving the way for personalized treatments and a deeper understanding of the disease’s etiology.
  • Patient advocacy groups and support networks are playing a crucial role in raising awareness and providing resources for Ankylosing Spondylitis Market patients.

Factors Driving Growth:

  • The rising prevalence of Ankylosing Spondylitis Market, particularly among young adults, underscores the need for effective treatment options and disease management strategies.
  • Advances in biologic therapies, such as monoclonal antibodies and Janus kinase (JAK) inhibitors, are expanding the treatment armamentarium for AS.
  • Early diagnosis and intervention are becoming standard practice, leading to better outcomes and improved quality of life for AS patients.
  • Awareness campaigns and educational initiatives are reducing diagnostic delays and promoting access to specialized care.

Ankylosing Spondylitis Market Challenges and Hurdles:

  • The high cost of biologic therapies for AS can limit access and affordability for some patients and healthcare systems.
  • Variability in disease progression and treatment response among AS patients necessitates personalized treatment plans.
  • Long-term safety and efficacy data for newer AS treatments are continually monitored, impacting treatment decisions and regulatory approvals.
  • The shortage of rheumatologists and specialists in some regions can delay diagnosis and treatment initiation.

Check the detailed table of contents of the report @

Segmentation of the Ankylosing Spondylitis Market:

Based on the Treatment Types

  • Medication
    1. TNF Inhibitors
    2. IL-17 Inhibitors
    3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    4. Other
  • Therapy
  • Surgery

Based on the End User

  • Ambulatory Surgery Centres
  • Hospitals
  • Clinics
  • Other

Regional Overview of the Ankylosing Spondylitis Market:

North America leads the AS market, driven by a high prevalence of AS and significant investments in rheumatology research and treatment.

Europe follows closely, with a strong focus on early diagnosis and advanced biologic therapies.

Asia Pacific is experiencing rapid growth, fueled by increasing awareness of AS and improving access to specialized care.

Emerging markets in Latin America and the Middle East & Africa are showing potential, driven by rising healthcare investments and awareness campaigns.

Buy this premium research report –

List of Key Players Ankylosing Spondylitis Market:

AbbVie Inc., Novartis AG, Pfizer, Inc., Eli Lilly and Company, Johnson & Johnson, Amgen, Inc., UCB S.A., Celgene Corporation (a Bristol-Myers Squibb Company), Boehringer Ingelheim International GmbH, Biogen Inc., Gilead Sciences, Inc., Merck & Co., Inc., Mylan N.V. (Viatris Inc.), Abbott Laboratories and Roche Holding AG.

Browse More Research Topic on Healthcare Sector Related Reports:

The Global Fructooligosaccharides (FOS) Market Size accounted for USD 3.1 Billion in 2022 and is projected to achieve a market size of USD 6.9 Billion by 2032 growing at a CAGR of 8.5% from 2023 to 2032.

The Global Perfusion Systems Market Size accounted for USD 1.3 Billion in 2022 and is projected to achieve a market size of USD 1.9 Billion by 2032 growing at a CAGR of 4.5% from 2023 to 2032.

The Global Monoclonal Antibodies Market size was valued at USD 195.6 Billion in 2022 and is projected to attain USD 612.2 Billion by 2032 mounting at a CAGR of 12.3% from 2023 to 2032.

Browse Our Official Website Press release:

About Acumen Research and Consulting:

Acumen Research and Consulting is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

For Latest Update Follow Us on Twitter , Instagram and LinkedIn

Contact Us:

Mr. Richard Johnson

Acumen Research and Consulting

USA: +13474743864

India: +918983225533


Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More